Zimmer Biomet Holdings, Inc. (ZBH)

Market Cap	21.97B
Revenue (ttm)	7.68B
Net Income (ttm)	903.80M
Shares Out	199.06M
EPS (ttm)	4.43
PE Ratio	24.91
Forward PE	13.39
Dividend	$0.96 (0.87%)
Ex-Dividend Date	Mar 31, 2025

Volume	1,295,197
Open	111.25
Previous Close	111.24
Day's Range	109.33 - 112.31
52-Week Range	97.69 - 133.90
Beta	1.04
Analysts	Buy
Price Target	124.15 (+12.49%)
Earnings Date	May 1, 2025

About ZBH

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open hear...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1927
• Employees: 17,000
• Stock Exchange: NYSE
• Ticker Symbol: ZBH
• Website: https://www.zimmerbiomet.com

Financial Performance

In 2024, Zimmer Biomet Holdings's revenue was $7.68 billion, an increase of 3.85% compared to the previous year's $7.39 billion. Earnings were $903.80 million, a decrease of -11.74%.

Analyst Forecast

According to 22 analysts, the average rating for ZBH stock is "Buy." The 12-month stock price forecast is $124.15, which is an increase of 12.49% from the latest price.

Price Target

$124.15

(12.49% upside)

Analyst Consensus: Buy